Overview

Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors

Status:
Completed
Trial end date:
2017-10-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, tolerability, pharmacokinetic profile and treatment effect of a new drug known as BGB-283 in patients with solid tumours.
Phase:
Phase 1
Details
Lead Sponsor:
BeiGene